Long‐term effects of insulin‐like growth factor (IGF)‐I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency
- 1 April 1995
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 42 (4) , 399-407
- https://doi.org/10.1111/j.1365-2265.1995.tb02649.x
Abstract
The aim of this investigation was to study the effect of relatively high dose IGF-I therapy given for several months, on serum levels of IGF-I, IGF-II and IGFBP-3, and on IGF-I pharmacokinetics in patients with growth hormone insensitivity due to GH receptor dysfunction. Two adolescent subjects from Ecuador were treated with recombinant IGF-I at a dosage of 120 micrograms/kg s.c. twice daily, in combination with a GnRH analogue for 8 months. Serum was sampled at baseline and at 3-8 months, for determination of IGF-I, IGF-II and IGFBP-3 by radioimmunoassay, and for evaluation of IGFBPs and IGFBP-3 protease activity by Western ligand blot and protease assay, respectively. Peak serum IGF-I levels ranged from 272 to 492 micrograms/l. Mean serum IGF-II levels were decreased concurrently with the increase in IGF-I. Serum IGFBP-3 levels failed to rise with prolonged IGF-I treatment. There was no apparent change in the half-life of IGF-I during the treatment period. IGF-I administration does not increase serum levels of IGFBP-3 or significantly alter IGF-I pharmacokinetics.Keywords
This publication has 21 references indexed in Scilit:
- Growth hormone (GH) insensitivity due to primary GH receptor deficiencyEndocrine Reviews, 1994
- The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3Journal of Clinical Endocrinology & Metabolism, 1993
- Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndromeJournal of Clinical Endocrinology & Metabolism, 1993
- Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.Journal of Clinical Investigation, 1993
- Measurement and characterization of insulin-like growth factor binding protein-3 in human biological fluids: discrepancies between radioimmunoassay and ligand blottingEndocrinology, 1992
- Expression of serum insulin-like growth factors, insulin-like growth factor-binding proteins, and the growth hormone-binding protein in heterozygote relatives of Ecuadorian growth hormone receptor deficient patientsJournal of Clinical Endocrinology & Metabolism, 1992
- Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndromeHuman Mutation, 1992
- Effects of continuous infusion of insulin-like growth factor I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized ratEndocrinology, 1992
- Laron Dwarfism and Mutations of the Growth Hormone–Receptor GeneNew England Journal of Medicine, 1989
- Insulin-like growth factors I and II in evaluation of growth retardationThe Journal of Pediatrics, 1986